Financial News

Markets:

Overview

News

Currencies

International

Treasuries

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

41.92 +0.08 (+0.19%)

Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Supernus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

SUPN Q3 deep dive: robust portfolio growth and integration priorities amid Indivior merger

Today 12:06 EDT

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) announced better-than-expected revenue in Q3 2026, with sales up 18.1% year on year t...

Via StockStory

Supernus (SUPN) Q3 2026 Earnings Call Transcript ↗

Today 11:44 EDT

Qelbree prescriptions surged 18% as revenue hit $226.8 million ahead of Indivior merger.

Via The Motley Fool

Topics Earnings

Supernus Pharmaceuticals Q3 Earnings Call Highlights ↗

October 29, 2026

Supernus Pharmaceuticals (NASDAQ:SUPN) reported record third-quarter revenue and higher sales across its growth portfolio, while management said its planned merger with Indivior Pharmaceuticals is...

Via MarketBeat

Topics Earnings

Supernus Pharmaceuticals (NASDAQ:SUPN) Beats Q3 Estimates and Raises Outlook as Indivior Merger Nears ↗

October 29, 2026

Via Chartmill

Supernus Pharmaceuticals (NASDAQ:SUPN) delivers impressive Q3 2026, full-year sales guidance is optimistic

October 29, 2026

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) beat Wall Street’s revenue expectations in Q3 2026, with revenue rising 18.1% year on...

Via StockStory

Supernus Pharmaceuticals earnings: what to look for from SUPN

October 27, 2026

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results this Thursday after market hours. Here’s what to ...

Via StockStory

Topics Artificial Intelligence

1 Russell 2000 Stock with Exciting Potential and 2 We Ignore

October 14, 2026

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resou...

Via StockStory

Topics Supply Chain

1 Healthcare Stock Worth Your Attention and 2 We Turn Down

October 09, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on...

Via StockStory

1 Unprofitable Stock with Impressive Fundamentals and 2 We Avoid

September 30, 2026

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...

Via StockStory

2 Growth Stocks to Add to Your Roster and 1 We Question

September 28, 2026

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr...

Via StockStory

Topics Credit Cards

3 Reasons SUPN is Risky and 1 Stock to Buy Instead

September 21, 2026

Over the last six months, Supernus Pharmaceuticals’s shares have sunk to $41.99, producing a disappointing 14.7% loss - a stark contrast to the S&P 500’s 16....

Via StockStory

Topics Stocks Supply Chain

Branded Pharmaceuticals Stocks Q2 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)

September 17, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Supernus Pharmaceuticals (NAS...

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 Cash-Heavy Stocks Walking a Fine Line

September 16, 2026

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...

Via StockStory

1 of Wall Street’s Favorite Stocks with Promising Prospects and 2 Facing Headwinds

September 08, 2026

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...

Via StockStory

3 Out-of-Favor Stocks We’re Skeptical Of

September 02, 2026

The past year hasn’t been kind to the stocks featured in this article. Each has tumbled to its lowest point in 12 months, leaving investors to decide whether...

Via StockStory

3 Small-Cap Stocks with Open Questions

August 25, 2026

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...

Via StockStory

1 Healthcare Stock with Exciting Potential and 2 We Ignore

August 18, 2026

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...

Via StockStory

Topics Retirement

Supernus Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript ↗

August 17, 2026

Supernus Pharmaceuticals (NASDAQ:SUPN) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs....

Via Benzinga

Topics Earnings

3 Russell 2000 Stocks We Approach with Caution

August 14, 2026

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ...

Via StockStory

Why Supernus Pharmaceuticals Stock Topped the Market Today ↗

August 03, 2026

It's effecting a "merger of equals" with a peer.

Via The Motley Fool

Supernus Pharmaceuticals Q2 Earnings Call Highlights ↗

August 03, 2026

Supernus Pharmaceuticals (NASDAQ:SUPN) and Indivior Pharmaceuticals announced a proposed all-stock, tax-free merger of equals that would create a central nervous system-focused biopharmaceutical...

Via MarketBeat

Topics Earnings

What's going on in today's pre-market session ↗

August 03, 2026

Via Chartmill

Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Q2 CY2026 Sales, Stock Jumps 24.9%

August 03, 2026

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 3...

Via StockStory

Supernus Pharmaceuticals Earnings: What To Look For From SUPN

August 02, 2026

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be reporting results this Tuesday after market hours. Here’s what to look for. S...

Via StockStory

Topics Artificial Intelligence

1 Cash-Producing Stock on Our Buy List and 2 That Underwhelm

July 16, 2026

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Via StockStory

1 Growth Stock to Stash and 2 We Turn Down

July 15, 2026

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr...

Via StockStory

Topics Artificial Intelligence

Branded Pharmaceuticals Stocks Q1 Teardown: Supernus Pharmaceuticals (NASDAQ:SUPN) Vs The Rest

June 22, 2026

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, incl...

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 of Wall Street’s Favorite Stocks We Approach with Caution

June 19, 2026

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...

Via StockStory

3 Reasons to Avoid SUPN and 1 Stock to Buy Instead

June 16, 2026

Over the last six months, Supernus Pharmaceuticals’s shares have sunk to $43.79, producing a disappointing 9.4% loss - a stark contrast to the S&P 500’s 9.3%...

Via StockStory

Topics Stocks Supply Chain

1 Cash-Heavy Stock on Our Watchlist and 2 Facing Challenges

June 05, 2026

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Financial News

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

Headline News about Supernus Pharmaceuticals, Inc. - Common Stock

Popular Pages